ClinicalTrials.gg
RecruitingNCT07547735Updated Apr 23, 2026

Phase II Clinical Trial of UC-MSCs in the Treatment of Knee Osteoarthritis

A Phase 2 interventional study of UC-MSCs and UC-MSCs in Knee Osteoarthritis, sponsored by Union Hospital, Tongji Medical College, Huazhong University of Science and Technology. Recruiting at 3 sites in China. Open to participants aged 40 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-04-23.

Sponsored by Union Hospital, Tongji Medical College, Huazhong University of Science and Technology · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Registered 1 year after the study started (first participant enrolled Mar 2025, registered Mar 2026).
  • Started Mar 2025; still recruiting 1 year 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
100
Allocation
Randomized
Ages
40 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 136 studies in Osteoarthritis, Knee with a site in China — 32 open to participants now, 32 under way, 4 of them phase 3. Osteoarthritis, Knee · China.

Planned enrollment
58th of 115
100 · median 100
Started
2025
with 9 others
Phase 2
9 of 136
3 open now
Primary completion
2027-05
later than 25 of 31 live
Registered
126th of 136
by date

Among the 136 studies in Osteoarthritis, Knee with a site in China, this one is the 58th largest by planned enrollment of the 115 interventional ones that give a count, is one of 10 that started in 2025, is one of 9 in phase 2, reaches primary completion later than 25 of the 31 other live ones, and was the 126th registered.

Osteoarthritis, Knee

3,297 studies on the registry are indexed under Osteoarthritis, Knee; 623 are open to participants now.

Browse Osteoarthritis, Knee studies →

Open to participants now

32 of the 136 studies in Osteoarthritis, Knee with a site in China are open now. Recruiting first, the newest first:

26 more — sign in →

All 32 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 384 Osteoarthritis, Knee studies recruiting now, 178 (46%) set no upper age limit and 113 (29%) stop at 75 or younger; 19 take children under 18; 39 take healthy volunteers.

This study: 40 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 136 studies in Osteoarthritis, Knee with a site in China, or all of them as a file.
02

Study summary

In recent years, the incidence rate and disability rate of osteoarthritis have continued to grow, and it has become a common chronic disease of elderly patients, second only to the "three highs", and poses a continuous threat to China's medical and health system and public health system. Knee osteoarthritis is the main type of osteoarthritis, ranking 11th in global disability diseases and 38th in disability adjusted life year loss, causing significant economic burden to patients, families, and society. At present, most of the treatment methods for KOA have limited efficacy, only relieving pain symptoms and cannot prevent cartilage damage and other tissue damage in the joints. Due to the limitations of adverse events, there is still no optimal treatment plan for KOA. Most studies believe that autologous mesenchymal stem cell transplantation is a new treatment method with good efficacy and good repair effect for mild to moderate cartilage defects. Given that there is currently no optimal treatment plan for KOA, human umbilical cord mesenchymal stem cell injection has potential development value and is of great significance for the treatment of KOA patients.

Read the detailed description

Osteoarthritis (OA) is a chronic inflammatory disease of the bone and joints, characterized by degenerative destruction of articular cartilage, subchondral bone sclerosis and osteophyte formation, and peripheral soft tissue inflammation and proliferation. Knee Osteoarthritis (KOA), which is negative and highly active, is the most common. Currently, there are approximately 1 billion KOA patients worldwide, with approximately 150 million patients in China, and the incidence rate increases with age. The clinical manifestation of KOA is repeated and prolonged bone and joint pain, which seriously affects the patient's quality of life, ultimately leading to joint structural damage and loss of function, causing a significant burden on individuals, families, and society. At present, there is a lack of effective treatment methods for KOA both domestically and internationally, and there is an urgent need to research new treatment strategies to meet clinical needs. Numerous studies have shown that local inflammation of the joint cavity and apoptosis of articular chondrocytes are the main pathological mechanisms of knee osteoarthritis. Therefore, the key to treating KOA is to inhibit the local inflammatory response of bone joints, promote chondrocyte regeneration, repair damaged joint surfaces, and restore their normal structure and function.

Mesenchymal Stem Cells (MSCs) are the most widely studied pluripotent stem cells. It exists in various tissues, has multidirectional differentiation potential, homing effect and powerful paracrine function, can regulate tissue microenvironment, promote damaged tissue repair through cell replacement, promote in-situ cell regeneration, anti-inflammatory and immune regulation and other mechanisms. Therefore, mesenchymal stem cell therapy has become the focus of KOA new therapy research. A large number of studies have shown that MSCs can be induced to differentiate into stable mature chondrocytes that can express proteoglycan and type II collagen. Fluorescently labeled MSCs could still be detected 10 weeks after injection into the joint cavity of osteoarthritis model animals, suggesting that MSCs homed in the injured articular cartilage tissue and participated in the regeneration and repair of the injured tissue. The effectiveness of MSCs therapy for KOA has been demonstrated in osteoarthritis models in different animals including rats, rabbits, sheep, pigs, and monkeys. MSCs from different sources can effectively inhibit the inflammatory response and chondrocyte injury in model animals, and stimulate the regeneration and repair of injured chondrocytes.

Based on the Phase I clinical trial that has entered the follow-up phase, the applicant is applying for a "Multi-center, randomized, double-blinded, placebo-controlled Phase II Clinical Trial of UC-MSCs for the Treatment of Knee Osteoarthritis". A total of 100 subjects are planned to be enrolled and randomly assigned in a 2:2:1 ratio to Treatment Group 1 (5.0 × 10⁶ cells/2.5 mL, 40 subjects), Treatment Group 2 (2.0 × 10⁷ cells/2.5 mL, 40 subjects) and Placebo group (20 subjects). The objective is to obtain a more comprehensive and direct assessment of the safety, efficacy, and optimal effective dose of UC-MSCs for knee osteoarthritis.

03

Conditions studied

  • Knee Osteoarthritis

Keywords

  • Knee Osteoarthritis; UC-MSCs; Cell Therapy; Efficiency; Safety
04

Who can participate

Ages eligible
40 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Prior to conducting any assessment, written must be obtained;
  2. Able to communicate well with researchers during screening, understand and comply with experimental requirements;
  3. Age range from 40 to 70 years old (including threshold), regardless of gender;
  4. Male weight ≥ 50 kg, female weight ≥ 45 kg, (BMI) within the range of 18-28 kg/m2 (including critical values);
  5. According to the diagnostic criteria for knee osteoarthritis in the "Guidelines for the Diagnosis and Treatment of Osteoarthritis (2018 Edition)", subjects diagnosed with knee osteoarthritis (see Annex 1 for details); The course of knee osteoarthritis is more than 4 weeks;

Other:

15) There are to MRI examination or unwillingness to undergo MRI examination; 16) , , AIDS, syphilis serological test positive pathogens; 17) Pregnant or lactating women, or male or female patients who tested positive for blood pregnancy during screening or have planned childbirth within 3 months after medication; 18) Patients who have received or attenuated live vaccines within one month before administration; 19) Patients who have participated in clinical trials of other drugs or devices within 3 months prior to administration; 20) Patients with poor compliance, poor communication skills, inability to adhere to follow-up, and inability to complete the entire trial; 21) The researchers believe that it is not suitable for participants to enter this experiment.

6) The target knee joint X-ray Kellgren Lawrence radiological grading (K-L IV grade) is II-III grade. Patients diagnosed with knee osteoarthritis on both sides should have non target knee joint symptoms, signs, and grading that do not exceed the target knee joint; 7) MRI examination shows partial or full layer damage to the cartilage of the knee joint; 8) A VAS score of ≥ 4 and ≤ 7 for knee joint pain at least 48 hours after discontinuing the use of all painkillers during screening; 9) Patients who use analgesic therapy (taking paracetamol/acetaminophen) to control local pain in the target knee joint agree to discontinue the use of similar analgesics 2 weeks prior to administration, and only allow NSAID as a rescue drug; Patients who use glucosamine, chondroitin, opioid drugs, or diacetate, glucosamine, etc. must agree to discontinue such drugs from 2 weeks prior to administration.

-

Exclusion criteria

Exclusion Criteria:

  • History of local/systemic treatment:

    1. Individuals with a history of knee joint infection, surgery, and radiation therapy within 6 months prior to administration;
    2. Combined instability of the knee joint (anterior and posterior cruciate ligaments, medial and lateral collateral ligaments), rupture, relaxation, or external deformity of the knee joint;
    3. According to researchers, diseases that may interfere with knee joint function assessment, such as symptomatic lower back pain, lumbar disc herniation, and hip joint pain in the target knee joint;
    4. According to the judgment of researchers, local diseases that may confuse knee joint function assessment include but are not limited to septic arthritis, reactive arthritis, clinically recurrent pseudogout, chondrocalcinosis, or joint fractures;
    5. Within 3 months prior to administration, any medication injection treatment (including intra-articular injection of growth factors, hormones, or sodium hyaluronate) or lavage surgery has been received in the knee joint (target side) cavity;
    6. Merge intra-articular or periarticular tumors (such as knee synovial chondroma, pigmented nodular synovitis, etc.);

      Systemic diseases and treatment history:

    7. Various serious systemic diseases such as neurological disorders, respiratory disorders, heart diseases ( grade III and above), and liver dysfunction (>3)× or AST>3×ULN, renal dysfunction Cr>2×ULN or BUN>2×ULN, coagulation dysfunction (>1.5), or severe hematological disorders (such as grade 3 or above anemia, (Hb)\<8 g/dL, grade 2 or above thrombocytopenia, \<75×10 \^ 9/L);
    8. Diagnosed as systemic inflammatory arthritis or connective tissue disease, including but not limited to rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, gout, Paget's disease, systemic lupus erythematosus, or other systemic diseases that may confuse KOA assessment (such as fibromyalgia);
    9. Subjects who receive long-term (>14 days) oral >5 mg/day within 3 months prior to administration, or who require long-term glucocorticoid treatment during the trial period;
    10. Previously received stem cell therapy;
    11. Uncontrolled hypertension is defined as systolic blood pressure (SBP)>160 mmHg or diastolic blood pressure (DBP)>100 mmHg during screening;
    12. Having a history of tumors, mental illness, severe diseases, hematological diseases, and long-term use of ;
    13. Have a history of alcohol and prohibited drug abuse;
    14. Has a history of to protein drugs;
Terms in these criteria, in plain language(16)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
100 participants (estimated)

Study arms

  • Experimental
    UC-MSCs Treatment Group 1

    Participants will receive conventional treatment plus 1 time of UC-MSCs (5×10\^6 UC-MSCs/2.5mL, single injection into the knee cavity).

    Drug: UC-MSCs

  • Experimental
    UC-MSCs Treatment Group 2

    Participants will receive conventional treatment plus 1 time of UC-MSCs (2×10\^7 UC-MSCs/2.5mL, single injection into the knee cavity).

    Drug: UC-MSCs

  • Placebo comparator
    Placebo Group

    Participants will receive conventional treatment plus 1 time of placebo (2.5mL normal saline containing 1 % human serum albumin, single injection into the knee cavity).

    Drug: placebo

Interventions

  • DrugUC-MSCs

    1 time of UC-MSCs (5×10\^6 UC-MSCs/2.5mL, single injection into the knee cavity

  • DrugUC-MSCs

    1 time of UC-MSCs (2×10\^7 UC-MSCs/2.5mL, single injection into the knee cavity).

  • Drugplacebo

    1 time of placebo (2.5mL normal saline containing 1 % human serum albumin, single injection into the knee cavity)

06

What researchers measure

Primary outcomes

  1. Changes in WOMAC score from baseline

    Time frame: From Baseline (0 Week) to post-dose, 4 weeks, 12 weeks, 24 weeks, and 48 weeks after treatment

Secondary outcomes

  1. Changes in VAS score from baseline

    Time frame: From Baseline (0 Week) to post-dose, 4 weeks, 12 weeks, 24 weeks, and 48 weeks after treatment]

  2. Changes in knee joint range of motion from baseline

    knee joint range of motion

    Time frame: From Baseline (0 Week) to 4 weeks, 12 weeks, 24 weeks, 48 weeks after treatment

  3. Changes in X-Kellgren-Lawrence grading

    Time frame: From Baseline (0 Week) to 24 weeks, 48 weeks after treatment

  4. Changes of MRI-Roberts cartilage repair score compared with baseline

    Time frame: From Baseline (0 Week) to 24 weeks, 48 weeks after treatment

  5. minimum joint space width (mJSW) from baseline

    Time frame: From Baseline (0 Week) to 24 weeks, 48 weeks after treatment

  6. Changes of cartilage thickness compared with baseline

    Time frame: From Baseline (0 Week) to 24 weeks, 48 weeks after treatment

  7. Changes of synovial inflammation score (reference MOAKS) compared with baseline

    Time frame: From Baseline (0 Week) to 24 weeks, 48 weeks after treatment

07

Study locations

3 of 3 sites recruiting
  • Guangzhou First People's Hospital
    Wuhan, China
    Recruiting
    • Jianwei Wang · Contact13316188653
  • Wuhan Fourth Hospital
    Wuhan, China
    Recruiting
    • Qingsong Zhang · Contact18627858073
  • Wuhan Third Hospital
    Wuhan, China
    Recruiting
    • Zhanghua Li · Contact18971610121
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2025 (actual). Primary completion is estimated for May 2027, 26 months after the start.

Of 43 non-industry phase 2 interventional studies under Osteoarthritis, Knee, half reached primary completion within 30 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 61. This study's planned 26 months is below that.

Counting every sponsor, half of 101 studies reached it within 20 months; a quarter within 12 and three quarters within 39.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 29, 2026
First posted
Apr 23, 2026
StartActual
Mar 20, 2025
Primary completionEst.
May 30, 2027
CompletionEst.
May 30, 2028
Last update
Apr 23, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 23, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07547735
Responsible party
Sponsor
First posted
Apr 23, 2026
Start date
Mar 20, 2025
Primary completion
May 30, 2027 (estimated)
Completion
May 30, 2028 (estimated)
Last update
Apr 23, 2026

Study contacts

Hongtao Tian, MD
Contact
tianhongtao@vip.163.com
18627171618
Wei Tong, MD
Contact
13437105155 ext. tongwei312@126

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion